Hamburg – Vattenfall has sold 49% of its shares in the Nordlicht 1 and Nordlicht 2 wind farm projects to BASF. The wind farm zone consists of two separate sites and is located in the German section of the North Sea, around 85 kilometres north of the island of Borkum. The two sites, Nordlicht 1 and Nordlicht 2, have planned capacities of approximately 980 MW and 630 MW, respectively. Full commissioning is scheduled for 2028, when a total of around six terawatt hours (TWh) of electricity is expected to be generated per year, enough to power 1.6 million German households. This makes the Nordlicht wind project the biggest offshore wind farm project that Vattenfall has realised to date. Construction is expected to start in 2026, subject to the final investment decision. Vattenfall is acting as developer and builder of both Nordlicht sites.A CMS team headed by partners Dr Holger Kraft and Dr Jacob Siebert advised Vattenfall on all legal aspects of the transaction. Vattenfall and BASF signed a Memorandum of Understanding with regard to the joint project in December of last year, when the CMS team likewise advised Vattenfall. CMS Germany Dr Holger Kraft, Lead Partner Dr Jacob Siebert, Lead Part­ner Dorothée Janzen, Partner, Com­mer­cial Mat­thi­as Sethmann, Principal Counsel Dr Christoph Löffler, Counsel Dr Stefan Kühl, Senior Associate Dr Christian Seeburger, Associate, all Corporate/M&A Dr Niklas Ganssauge, Partner Mathias Cordero, Senior Associate, both Real Estate & Public Christoff Soltau, Partner Dr Denis Schlimpert, Counsel Dr Robert Bodewig, Senior Associate, all Antitrust, Competition & Trade Dr Kerstin Block, Partner, Banking & Finance Prof. Malte Grützmacher, Partner, TMC Dr Nikolas Gregor, Partner, Intellectual Prop­erty Se­basti­an Belz, Counsel Katja Meisel, Senior Associate Knut Göring-Tisch, Associate, all Public Dr Arne Burmester, Principal Counsel  Birgit Wagner, Legal Manager Shae Lynn Washington, Legal Co­ordin­at­or  Sarah Przybylski, Senior Legal Specialist Edris Trabzadah, Senior Legal Specialist Jule Marie Holz, Legal Specialist, all Smart OperationsPress Con­tact presse@cms-hs. com

Frankfurt/Main – Bruker has agreed to acquire ELITechGroup, a provider of specialty in vitro diagnostic (IVD) systems, from TecFin S.à r.l., a controlled affiliate of PAI Partners, a pre-eminent private equity firm, for EUR 870 million in cash, excluding the carved out ELITech clinical chemistry business. The transaction is expected to close in the second quarter of 2024, subject to regulatory approvals and other customary closing conditions.A team of CMS Germany headed by lead partner Dr Hendrik Hirsch acted as lead transaction counsel on this landmark transaction for Bruker's MDx business covering all M&A aspects of the transaction, IVDR and other regulatory aspects, antitrust and FDI filings, the carve out of the clinical chemistry business and support on the employee consultation processes in France and the Netherlands. ELITechGroup, with over 500 employees and over 40 active patents, develops and commercializes innovative, proprietary molecular diagnostic (MDx) systems and assays, as well as niche biomedical systems and microbiology products. Its molecular diagnostic business accounts for the majority of the to-be-acquired revenues and provides the unique sample-to-answer (S2A) instruments InGenius® and Be-Genius® in the mid-to-high throughput MDx category with PCR diagnostic assays for infections and diseases. ELITechGroup, excluding the clinical chemistry business, achieved approximately EUR 150 million in revenues in 2023. ELITechGroup generates the majority of its revenues from Europe, with significant business also in North and Latin America. Its major R&D and production sites are in Italy, the United States, France and Germany. CMS Germany Dr Hendrik Hirsch, Partner, Co-Lead Dr Jacob Siebert, Partner, Co-Lead Dr Dirk Baukholt, Principal Counsel Dr Berrit Roth-Mingram, Counsel Dr Maximilian Stark, Senior Associate, all Corporate/M&A Dr Roland Wiring, Partner Lukas Burgdorff, Associate Noah Rodenkirchen, Associate, all Regulatory & Lifesciences Dr Thomas Hirse, Part­ner Se­basti­an Vautz, Senior Associate Lisa Dietrich, Associate, all IP Dr Michael Bauer, Partner Stefan Lehr, Partner Kai Neuhaus, Partner Moritz Pottek, Counsel Dr. Denis Schlimpert, Counsel Kirsten Baubkus-Gerard, Senior Associate David Rappenglück, As­so­ci­ate Be­ne­dikt Christian Voss, Associate, all Antitrust, Competition & Trade Dr Thomas de la Motte, Partner Dr Markus Pfaff, Partner Dr André Frischemeier, Partner Hatice Aykel, Counsel Alisa Brehm, Senior Associate Thomas Schaak, Senior Associate Dr Sait Dogan, Associate, all Banking & Finance  Dr André Lippert, Part­ner Con­stan­ze Schweidtmann, Associate, both Real Estate & Public Dr Boris Alles, Partner Dr Theresa Kipp, Senior Associate, both Labor, Employment & Pensions CMS France Benoît Gomel, Partner Vincent Desbenoit, Associate Dylan Allali, all Corporate/M&A Caroline Froger-Michon, Partner Aurélie Parchet, As­so­ci­ate Ca­m­ille Baumgarten, Associate Sophie Yin, all Em­ploy­ment Claire Vannini, Partner Eleni Moraïtou, Coun­sel Lilia-Ori­ana Dif, Associate Ariane Rolin, all Competition & EU  Jean-Bap­tiste Thiénot, Partner Anaïs Arnal, Associate, both Intellectual Property Laurine Mayer, Associate, TMC Alexandre Chazot, Counsel, Banking & Fin­ance  Thi­erry Granier, Partner Renaud Grob, Partner, both Tax Arnaud Valverde, Senior Associate, Real Estate Olivier Kuhn, Partner Cécile Rebiffé, Counsel Mylène Garrouste, all Dispute Res­ol­u­tion Kawthar Ben Khelil, Coun­sel Jean-Pierre Malili, Associate, both Public law/In­fra­struc­ture CMS Italy Massimo Trentino, Partner, Corporate/M&A Maria Letizia Patania, Partner, Lifescience & Healthcare Gian Marco Lettieri, Senior Associate, Employment & Pensions Giulio Poggioli, Counsel Valerio Giuseppe Daniele, As­so­ci­ate Francesca Durante, Junior As­so­ci­ate  Arianna Toccaceli, Junior Associate, all Banking & Finance CMS Luxembourg Gérard Maitrejean, Partner Miruna Poenaru, Coun­sel Max­imili­an Helfgen, Associate, all Corporate/M&A CMS UK Jack Letson, Partner Lindsay McAllister, Associate, both Corporate/M&A David Dennis, Partner, Commercial CMS Netherlands Pieter van Duijvenvoorde, Partner Robert Jong, both Corporate/M&A Nigel Henssen Fleur van Assendelft de Coningh, both Employment Edmon Oude Elferink, Partner Marijke van der Vossen, both Antitrust, Competition & Trade CMS Serbia Radivoje Petrikić, Partner Mila Drljević, both Corporate/M&A CMS Austria Dieter Zandler, Partner Vanessa Horaceck, both Competition & EU CMS Ukraine Maria Orlyk, Partner Diana Valyeyeva CMS Turkiye Döne Yalçın, Partner Arcan Kemahlı,  Sa­ba­hat­tin Öztemiz Taner ElmasPress Con­tact presse@cms-hs. com

Stuttgart – The founder of medical laboratory MVZ Laaff, Prof. Helmut Laaff, has sold MVZ Laaff GmbH with its facilities in Freiburg, Heilbronn and Ulm to the amedes Group. amedes is a leading German lab services provider, operating a number of healthcare centres throughout Germany with different specialisations. MVZ Laaff provides services in fields of medicine including derma­to­path­o­logy, general pathology, immunohistology, molecular pathology and cytology, and is one of the leading laboratories in these specialist areas. Details of the transaction were not disclosed.A CMS team headed by lead partner Dr Christoph Lächler advised Prof. Helmut Laaff on all legal aspects of the transaction. The sale took place by way of an auction process. A particular focus of the advice was on structuring the transaction and the associated regulatory issues. CMS Germany Dr Christoph Lächler, Lead Part­ner Stefan-Ul­rich Müller, Partner Dr Jacob Siebert, Partner Viktoria Barthel, Senior Associate Tobias Kalski, Senior As­so­ci­ate An­dreas Kazmaier, Associate, all Corporate/M&A Dr Roland Wiring, Partner Dr Siham Hidar, Senior Associate, both Regulatory Dr Harald Kahlenberg, Partner Angelika Wieczorkowski, Senior Associate, both Antitrust, Competition & Trade Dr Stefan Voss, Partner Lukas Potstada, Counsel, both Real Estate Dr Martin Mohr, Partner, TaxPress Con­tact presse@cms-hs. com

Stuttgart – The SYNLAB Group, a leading provider of medical diagnostic services and specialist tests in Europe, has sold its Veterinary Diagnostics business (SYNLAB VET) to a subsidiary of US group...

Munich – Factor Eleven, a leading digital marketing software company, announces a strategic collaboration with Armira, an investment holding company focused on family businesses and tech­no­logy. The...

Hamburg – Antin Infrastructure Partners (“Antin”) has acquired a majority stake in Blue Elephant Energy AG (“BEE”) via its flagship Fund V. The deal is aimed at supporting BEE’s growth strategy...

Hamburg – International retail and services company Otto Group has acquired a majority stake in Swiss company Medgate Holding AG. Medgate Holding is a leading provider of digital health services, including...

Hamburg-based DAL Deutsche Afrika-Linien GmbH & Co. KG, which is part of the Rantzau Group, has sold its container liner service to Hapag-Lloyd AG. The transaction also includes the worldwide agency business...

Hamburg – UK-based PE fund IK Partners has signed an agreement to acquire a majority interest in STEIN HGS GmbH from Lennertz & Co, an owner-managed family office based in Hamburg, and company founder...

Stuttgart – ADS-TEC Energy GmbH, which describes itself as a world-leading provider of battery-buffered ultrafast charging technology, has completed a business combination with European Sustainable...

Munich – AFINUM Siebte Beteili­gungs­gesell­schaft mbH & Co. KG, which is advised by Afinum Management GmbH, has signed an agreement to sell Garz & Fricke Holding GmbH to Seco S.p.A., a listed Italian...